Mirae Asset Global ETFs Holdings
VERV

Mirae Asset Global ETFs Holdings’s Verve Therapeutics VERV Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-86,613
Closed -$973K – 3156
2025
Q2 		$973K Sell
86,613
-54,114
-38% -$308K ﹤0.01% 1455
2025
Q1 		$647K Sell
140,727
-4,022
-3% -$26.9K ﹤0.01% 1728
2024
Q4 		$816K Buy
144,749
+20,483
+16% +$116K ﹤0.01% 1658
2024
Q3 		$601K Sell
124,266
-19,761
-14% -$115K ﹤0.01% 1829
2024
Q2 		$702K Buy
+144,027
New +$905K ﹤0.01% 1645

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's VERV Position: Q3 2025 in Review

Mirae Asset Global ETFs Holdings sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 86,613 shares — an estimated $973K sold.

Mirae Asset Global ETFs Holdings first reported a position in VERV in Q2 2024 and held it in 5 quarters. The position peaked at $973K in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Mirae Asset Global ETFs Holdings reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Mirae Asset Global ETFs Holdings sold 86,613 Verve Therapeutics shares in Q3 2025, an estimated $973K.
  • Mirae Asset Global ETFs Holdings first reported a position in Verve Therapeutics in Q2 2024 and held it in 5 quarters.
  • Mirae Asset Global ETFs Holdings's Verve Therapeutics position peaked at $973K in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q3 2025, filed 14 Nov 2025.